


Drug Safety Evaluation

Fourth Edition

Shayne Cox Gad and Dexter W. Sullivan, Jr.



WILEY

DRUG SAFETY EVALUATION

DRUG SAFETY EVALUATION

Fourth Edition

SHAYNE COX GAD
Gad Consulting Services

DEXTER W. SULLIVAN, JR.
Gad Consulting Services

WILEY

This edition first published 2023
© 2023 John Wiley & Sons, Inc.

Edition History

John Wiley & Sons (1e, 2003; 2e, 2009; 3e, 2017)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Shayne Cox Gad and Dexter W. Sullivan, Jr. to be identified as the authors of this work has been asserted in accordance with law.

Registered Office

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty

In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Gad, Shayne C., 1948- author. | Sullivan, Dexter W., Jr. author.

Title: Drug safety evaluation / Shayne Cox Gad, Dexter W. Sullivan Jr.

Description: 4th edition. | Hoboken, NJ : Wiley, 2023. | Includes bibliographical references and index.

Identifiers: LCCN 2022042520 (print) | LCCN 2022042521 (ebook) | ISBN

9781119755852 (cloth) | ISBN 9781119755869 (adobe pdf) | ISBN

9781119755876 (epub)

Subjects: MESH: Drug Evaluation, Preclinical | Drug Evaluation | Product Surveillance, Postmarketing

Classification: LCC RA1238 (print) | LCC RA1238 (ebook) | NLM QV 771 |

DDC 615/.19—dc23/eng/20221110

LC record available at <https://lcn.loc.gov/2022042520>

LC ebook record available at <https://lcn.loc.gov/2022042521>

Cover Design: Wiley

Cover Image: © VICTOR HABBICK VISIONS/Getty Images

Set in 10/12pt Times LT Std by Straive, Chennai, India

*To my beloved Novie Beth, for years of love and support, and to my aunt Ernestine, who is
our matron and always a firecracker.*

—Shayne Cox Gad

*To Adrienne and Ayden, for your patience and support, and to my mother, Debby Mandeville,
who never fails to inspire me with her courage.*

—Dexter W. Sullivan, Jr.

ACKNOWLEDGMENT

Katina Gad's support and assistance were essential to the completion of this book.

CONTENTS

| | |
|------------------------------------------------------------------------------------------|-------------|
| PREFACE | xxix |
| ABOUT THE AUTHORS | xxx |
| 1 The Drug Development Process and The Global Pharmaceutical Marketplace | 1 |
| 1.1 Introduction | 1 |
| 1.2 The Marketplace | 1 |
| 1.3 History of Modern Therapeutics | 7 |
| 1.4 The Drug Development Process | 11 |
| 1.5 Strategies For Development: Large Versus Small Company or The Short Versus Long Game | 12 |
| 1.5.1 Do Only What You Must (The Short Game) | 13 |
| 1.5.2 Minimize the Risk of Subsequent Failure | 13 |
| 1.6 Safety Assessment And The Evolution Of Drug Safety | 14 |
| 1.7 The Three Stages of Drug Safety Evaluation In The General Case | 16 |
| References | 17 |
| 2 Regulation of Human Pharmaceutical Safety: Routes To Human Use and Market | 19 |
| 2.1 Introduction | 19 |
| 2.2 Brief History of Us Pharmaceutical Law | 19 |
| 2.2.1 1906: Pure Food and Drug Act | 19 |
| 2.2.2 1938: Food, Drug, and Cosmetic Act | 21 |
| 2.2.3 1962: Major Amendment | 23 |
| 2.2.4 1992, 1997, 2002, 2007, 2012, and 2017: PDUFA, FDAMA, and FDARA | 24 |
| 2.2.5 PREA: The Pediatric Research Equity Act | 27 |
| 2.2.6 ICH: International Conference on Harmonization | 27 |
| 2.2.7 Electronic Recordings: Electronic Submissions Impact | 27 |
| 2.2.8 COVID-19 | 27 |
| 2.3 Fdama Summary: Consequences and Other Regulations | 28 |
| 2.4 Overview of us Regulations | 28 |
| 2.4.1 Regulations: General Considerations | 28 |
| 2.4.2 Regulations: Human Pharmaceuticals | 28 |

| | | |
|--------|-----------------------------------------------------------------------------------|----|
| 2.4.3 | Regulations: Environmental Impact | 30 |
| 2.4.4 | Regulations: Antibiotics | 30 |
| 2.4.5 | Regulations: Biologics | 30 |
| 2.4.6 | Regulations Versus Law | 31 |
| 2.5 | Organizations Regulating Drug And Device Safety In The United States | 32 |
| 2.6 | Process Of Pharmaceutical Product Development and Approval | 32 |
| 2.7 | Testing Guidelines | 34 |
| 2.7.1 | Toxicity Testing: Traditional Pharmaceuticals | 34 |
| 2.7.2 | General or Systematic Toxicity Assessment | 34 |
| 2.7.3 | Genetic Toxicity Assessment | 34 |
| 2.7.4 | Safety Pharmacology | 36 |
| 2.7.5 | Local Tissue Tolerance | 36 |
| 2.7.6 | Reproductive and Developmental | 37 |
| 2.7.7 | Carcinogenicity | 37 |
| 2.7.8 | Toxicity Testing: Biotechnology Products | 37 |
| 2.8 | Toxicity/Safety Testing: Cellular And Gene Therapy Products | 39 |
| 2.8.1 | Cellular Therapies | 40 |
| 2.8.2 | Gene Therapies | 40 |
| 2.8.3 | ex vivo | 40 |
| 2.8.4 | in vivo | 40 |
| 2.8.5 | Preclinical Safety Evaluation | 41 |
| 2.8.6 | Basic Principles for Preclinical Safety Evaluation of Cellular and Gene Therapies | 41 |
| 2.8.7 | Additional Considerations for Cellular Therapies | 41 |
| 2.8.8 | Additional Considerations for Gene Therapies | 41 |
| 2.9 | Toxicity Testing: Special Cases | 41 |
| 2.9.1 | Oral Contraceptives | 42 |
| 2.9.2 | Life-Threatening Diseases (Compassionate Use) | 42 |
| 2.9.3 | Vaccines | 42 |
| 2.9.4 | Oncology Drugs and Imaging Agents | 43 |
| 2.9.5 | Optical Isomers | 43 |
| 2.9.6 | Special Populations: Pediatric and Geriatric Claims | 43 |
| 2.9.7 | Orphan Drugs | 45 |
| 2.9.8 | Expedited and Augmented Routes to Approval (Once you have an IND) | 45 |
| 2.9.9 | Botanical Drug Products | 45 |
| 2.9.10 | Types of New Drug Applications (NDAs) | 48 |
| 2.10 | International Pharmaceutical Regulation and Registration | 48 |
| 2.10.1 | International Council for Harmonization | 48 |
| 2.10.2 | Other International Considerations | 52 |
| 2.10.3 | Safety Pharmacology | 58 |
| 2.11 | Combination Products | 58 |
| 2.11.1 | Device Programs That Are CDER and CBRH Each Will Administer | 59 |
| 2.11.2 | Coordination | 59 |
| 2.11.3 | Submissions | 59 |
| 2.12 | Meetings And Submissions To Fda Toxicologists | 63 |
| 2.13 | Conclusion | 64 |
| | References | 64 |
| | Further Reading | 66 |

| | | |
|----------|-----------------------------------------------------------------------------------------------------------------------|-----------|
| 3 | Data Mining: Sources of Information For Consideration In Study And Program Design and In Safety Evaluation | 67 |
| 3.1 | Introduction 67 | |
| 3.1.1 | Claims 67 | |
| 3.1.2 | Time and Economies 67 | |
| 3.1.3 | Prior Knowledge 67 | |
| 3.1.4 | Miscellaneous Reference Sources 68 | |
| 3.1.5 | Search Procedure 70 | |
| 3.1.6 | Monitoring Published Literature and Other Research in Progress 70 | |
| 3.1.7 | Kinds of Information 71 | |
| 3.1.8 | Toxic Release Inventory (TRI) 71 | |
| 3.1.9 | Material Safety Data Sheets (MSDS) 71 | |
| 3.1.10 | Canadian Centre for Occupational Health and Safety (CCINFO) 72 | |
| 3.1.11 | Pollution and Toxicology (POLTOX) 72 | |
| 3.1.12 | Medline 72 | |
| 3.2 | Pc-Based Information Products: Laser Disc 72 | |
| 3.2.1 | International Veterinary Pathology Slide Bank (Ivpsb) 72 | |
| 3.3 | Conclusion 73 | |
| | References 73 | |
| | Further Reading 74 | |
| 4 | Electronic Records, Reporting, and Submission: eCTD and Send | 75 |
| 4.1 | Introduction 75 | |
| 4.2 | Submission of Send Data In Module 4 of The eCTD 76 | |
| 4.3 | Send Background 76 | |
| 4.4 | Send Regulatory 77 | |
| 4.5 | Send Features 77 | |
| 4.6 | Send Study Submission Package 80 | |
| 4.7 | Determination of Studies That Need Data To Be Submitted As Send Files 80 | |
| 4.7.1 | FDA Center 80 | |
| 4.7.2 | Type of Application 80 | |
| 4.7.3 | Study Start Date 80 | |
| 4.8 | Storage of Files At The Fda 81 | |
| 4.9 | Recommended Regulatory Resources 81 | |
| | References 81 | |
| 5 | Screens in Safety and Hazard Assessment | 83 |
| 5.1 | Introduction 83 | |
| 5.2 | Characteristics of Screens 84 | |
| 5.3 | Uses of Screens 86 | |
| 5.4 | Types of Screens 87 | |
| 5.4.1 | Single Stage 87 | |
| 5.4.2 | Sequential 87 | |
| 5.4.3 | Tier (or Multistage) 87 | |
| 5.5 | Criterion: Development And Use 87 | |
| 5.6 | Analysis Of Screening Data 88 | |
| 5.7 | Univariate Data 89 | |
| 5.7.1 | Control Charts 89 | |
| 5.7.2 | Central Tendency Plots 90 | |
| 5.7.3 | Multivariate Data 90 | |
| 5.7.4 | The Analog Plot 91 | |
| | References 92 | |

| | | |
|----------|------------------------------------------------------------------------------------|------------|
| 6 | Formulations, Routes, and Dosage Regimens | 95 |
| 6.1 | Introduction | 95 |
| 6.2 | Mechanisms | 97 |
| 6.2.1 | Local Effects | 97 |
| 6.2.2 | Absorption and Distribution | 98 |
| 6.2.3 | Metabolism | 99 |
| 6.3 | Common Routes | 99 |
| 6.3.1 | Dermal Route | 99 |
| 6.3.2 | Parenteral Routes | 100 |
| 6.3.3 | Bolus versus Infusion | 102 |
| 6.3.4 | Oral Route | 103 |
| 6.3.5 | Minor Routes | 111 |
| 6.3.6 | Route Comparisons and Contrasts | 113 |
| 6.4 | Formulation Of Test Materials | 113 |
| 6.4.1 | Preformulation | 114 |
| 6.4.2 | Dermal Formulations | 117 |
| 6.4.3 | Interactions Between Skin, Vehicle, and Test Chemical | 119 |
| 6.4.4 | Oral Formulations | 120 |
| 6.4.5 | Parenteral Formulations | 121 |
| 6.5 | Dosing Calculations | 122 |
| 6.6 | Calculating Material Requirements | 122 |
| 6.7 | Excipients | 123 |
| 6.7.1 | Regulation of Excipients | 123 |
| | References | 128 |
| 7 | Mechanisms And End Points Of Drug Toxicity | 131 |
| 7.1 | Manifestations | 131 |
| 7.2 | Mechanisms Of Toxicity | 132 |
| 7.3 | End Points Measured In General Toxicity Studies | 132 |
| 7.3.1 | Clinical Observations | 132 |
| 7.3.2 | Body Weights | 132 |
| 7.3.3 | Food and Water Consumption | 133 |
| 7.3.4 | Clinical Signs | 133 |
| 7.3.5 | Clinical Chemistry and Pathology | 136 |
| 7.3.6 | Hematology | 137 |
| 7.3.7 | Gross Necropsy and Organ Weights | 137 |
| 7.3.8 | Histopathology | 137 |
| 7.3.9 | Ophthalmology | 140 |
| 7.3.10 | Cardiovascular Function | 140 |
| 7.3.11 | Neurotoxicology | 140 |
| 7.3.12 | Immunotoxicology | 140 |
| 7.3.13 | Imaging and Telemetry | 141 |
| 7.4 | Complications | 141 |
| | References | 141 |
| 8 | Pilot Toxicity Testing In Drug Safety Evaluation: MTD and DRF | 143 |
| 8.1 | Introduction | 143 |
| 8.2 | Range-Finding Studies | 143 |
| 8.2.1 | Lethality Testing | 144 |
| 8.2.2 | Using Range-Finding Lethality Data in Drug Development: The Minimum Lethal Dose | 150 |
| 8.3 | Acute Systemic Toxicity Characterization | 153 |
| 8.3.1 | Minimal Acute Toxicity Test | 153 |

| | | |
|-----------|------------------------------------------------------------|------------|
| 8.3.2 | Complete Acute Toxicity Testing | 157 |
| 8.3.3 | Acute Toxicity Testing with Nonrodent Species | 161 |
| 8.3.4 | Factors that Can Affect Acute Tests | 163 |
| 8.3.5 | Selection of Dosages | 164 |
| 8.4 | Screens | 165 |
| 8.4.1 | General Toxicity Screens | 165 |
| 8.4.2 | Specific Toxicity Screening | 168 |
| 8.5 | Pilot And DRF Studies | 169 |
| | References | 171 |
| 9 | Repeat-Dose Toxicity Studies | 173 |
| 9.1 | Objectives | 173 |
| 9.2 | Regulatory Considerations | 175 |
| 9.2.1 | Good Laboratory Practices | 175 |
| 9.2.2 | Animal Welfare Act | 175 |
| 9.2.3 | Regulatory Requirements for Study Design | 176 |
| 9.3 | Study Design and Conduct | 176 |
| 9.3.1 | Animals | 176 |
| 9.3.2 | Routes and Setting Doses | 177 |
| 9.3.3 | Parameters to Measure | 178 |
| 9.3.4 | Study Designs | 179 |
| 9.4 | Study Interpretation and Reporting | 180 |
| 9.5 | Read Across For Program Wide Evaluation | 180 |
| | References | 181 |
| 10 | Genotoxicity | 183 |
| 10.1 | ICH Test Profile | 183 |
| 10.2 | DNA Structure | 184 |
| 10.2.1 | Transcription | 185 |
| 10.2.2 | Translation | 185 |
| 10.2.3 | Gene Regulation | 185 |
| 10.2.4 | DNA Repair | 185 |
| 10.2.5 | Error-Prone Repair | 186 |
| 10.2.6 | Mismatch Repair | 186 |
| 10.2.7 | The Adaptive Repair Pathway | 186 |
| 10.2.8 | Plasmids | 186 |
| 10.2.9 | Plasmids and DNA Repair | 187 |
| 10.2.10 | Nature of Point Mutations | 187 |
| 10.2.11 | Suppressor Mutations | 187 |
| 10.2.12 | Adduct Formation | 187 |
| 10.2.13 | Mutations Due to Insertion Sequences | 188 |
| 10.2.14 | The Link Between Mutation and Cancer | 188 |
| 10.2.15 | Genotoxic Versus Nongenotoxic Mechanisms of Carcinogenesis | 188 |
| 10.2.16 | Genetic Damage and Heritable Defects | 189 |
| 10.2.17 | Reproductive Effects | 190 |
| 10.3 | Cytogenetics | 190 |
| 10.3.1 | Cytogenetic Damage and Its Consequences | 190 |
| 10.3.2 | Individual Chromosomal Damage | 190 |
| 10.3.3 | Chromosome Set Damage | 191 |
| 10.3.4 | Test Systems | 191 |
| 10.3.5 | <i>In vitro</i> Test Systems | 192 |
| 10.3.6 | Bacterial Mutation Tests | 194 |
| 10.3.7 | Controls | 195 |

- 10.3.8 Plate Incorporation Assay 198
- 10.3.9 Eukaryotic Mutation Tests 199
- 10.3.10 *In vitro* Tests for the Detection of Mammalian Mutation 199
- 10.3.11 *In Vivo* Mammalian Mutation Tests 207
- 10.4 *In vitro* Cytogenetic Assays 208
 - 10.4.1 Cell Types 208
 - 10.4.2 Chinese Hamster Cell Lines 208
 - 10.4.3 Human Peripheral Blood Lymphocytes 208
 - 10.4.4 Positive and Negative Controls 209
 - 10.4.5 Treatment of Cells 209
 - 10.4.6 Scoring Procedures 210
 - 10.4.7 Data Recording 210
 - 10.4.8 Presentation of Results 210
- 10.5 *In vivo* Cytogenetic Assays 210
 - 10.5.1 Somatic Cell Assays 211
 - 10.5.2 Germ Cell Assays 211
 - 10.5.3 Heritable Chromosome Assays 211
 - 10.5.4 Germ Cell Cytogenetic Assays 211
- 10.6 Sister Chromatid Exchange Assays 212
 - 10.6.1 Relevance of SCE in Terms of Genotoxicity 212
 - 10.6.2 Experimental Design 212
- 10.7 How to Deal with Positive Test Results 213
- References 214

11 QSAR Tools For Drug Safety 223

- 11.1 Structure–Activity Relationships 223
 - 11.1.1 Basic Assumptions 224
 - 11.1.2 Molecular Parameters of Interest 224
- 11.2 Sar Modeling Methods 224
- 11.3 Applications In Toxicology 226
 - 11.3.1 Metabolism 227
 - 11.3.2 Reproductive 227
 - 11.3.3 Eye Irritation 227
 - 11.3.4 Lethality 227
 - 11.3.5 Carcinogenicity 228
- 11.4 Genotoxicity 230
 - 11.4.1 QSAR for Mutagenicity 230
- 11.5 Comparison Of Available Models/Applications 231
 - 11.5.1 QSAR of Metabolism 231
 - 11.5.2 Meteor 232
 - 11.5.3 Derek 232
 - 11.5.4 Leadscope 233
 - 11.5.5 VEGA 233
 - 11.5.6 Derek versus Leadscope 235
- 11.6 Near Neighbor Surrogates And Their Use 237
- References 238

12 Toxicogenomics 241

- 12.1 Introduction 241
- 12.2 Uses of Toxicogenomics 242
- References 243

| | |
|---------------------------------------------------------------------------------------------------------|------------|
| 13 Immunotoxicology In Drug Development | 247 |
| 13.1 Introduction | 247 |
| 13.2 Overview of The Immune System | 249 |
| 13.3 Immunotoxic Effects | 250 |
| 13.4 Immunosuppression | 251 |
| 13.4.1 Immunosuppressive Drugs | 253 |
| 13.5 Immunostimulation | 256 |
| 13.5.1 Hypersensitivity (or Allergenicity) | 257 |
| 13.5.2 Photosensitization | 259 |
| 13.5.3 Autoimmunity | 260 |
| 13.6 Regulatory Positions | 262 |
| 13.6.1 CDER Guidance for Investigational New Drugs | 263 |
| 13.7 Evaluation of The Immune System | 265 |
| 13.7.1 Immunopathologic Assessments | 267 |
| 13.7.2 Humoral (Innate) Immune Response and Possible Entry Points for Immunotoxic Actions | 268 |
| 13.7.3 Cell-Mediated Immunity | 271 |
| 13.8 Nonspecific Immunity Function Assay | 273 |
| 13.8.1 Natural Killer Cell Assays | 273 |
| 13.8.2 Macrophage Function | 273 |
| 13.8.3 Mast Cell/Basophil Function | 273 |
| 13.9 T-Cell-Dependent Antibody Response (TDAR) | 274 |
| 13.9.1 Treatment | 274 |
| 13.9.2 Hypersensitivity | 275 |
| 13.9.3 Local Lymph Node Assay (LLNA) | 277 |
| 13.9.4 Photosensitization | 279 |
| 13.10 Approaches To Compound Evaluation | 280 |
| 13.10.1 Use of <i>in vivo</i> Tests | 280 |
| 13.10.2 Use of <i>in vitro</i> Tests | 281 |
| 13.10.3 Assessment of Immunotoxicity and Immunogenicity/Allergenicity of Biotechnology-Derived Drugs | 282 |
| 13.10.4 Suggested Approaches to Evaluation of Results | 282 |
| 13.11 Problems And Future Directions | 283 |
| 13.11.1 Data Interpretation | 284 |
| 13.11.2 Appropriate Animal Models | 284 |
| 13.11.3 Indirect Immunotoxic Effects | 284 |
| 13.11.4 Hypersensitivity Tests | 284 |
| 13.11.5 Anaphylaxis Tests | 284 |
| 13.11.6 Autoimmunity | 285 |
| 13.11.7 Functional Reserve Capacity | 285 |
| 13.11.8 Significance of Minor Perturbations | 285 |
| 13.11.9 Biotechnology Products | 286 |
| 13.12 Summary | 286 |
| References | 286 |
| | |
| 14 Nonrodent Animal Studies | 293 |
| 14.1 Introduction | 293 |
| 14.2 Comparison Between Rodent And Nonrodent Experimental Design | 293 |
| 14.2.1 Number of Animals | 293 |
| 14.3 Differences In Study Activities | 294 |
| 14.3.1 Blood Collection | 294 |
| 14.3.2 Dosing | 294 |
| 14.3.3 Handling of Animals | 294 |
| 14.3.4 Behavioral Evaluation | 294 |

- 14.4 Nonrodent Models 294
- 14.5 Dog 294
 - 14.5.1 Environmental and Dietary Requirements 294
 - 14.5.2 Common Study Protocols 295
 - 14.5.3 General Study Activities 296
 - 14.5.4 Advantages and Disadvantages 297
- 14.6 The Ferret 297
 - 14.6.1 Environmental and Dietary Requirements 297
 - 14.6.2 Study Protocols 298
 - 14.6.3 General Study Activities 298
 - 14.6.4 Advantages and Disadvantages 299
- 14.7 The Pig 299
 - 14.7.1 Background 299
 - 14.7.2 Clinical Laboratory 300
 - 14.7.3 Xenobiotic Metabolism 301
 - 14.7.4 Dermal Toxicity 302
 - 14.7.5 Cardiovascular Toxicity 303
 - 14.7.6 Advantages and Disadvantages 303
- 14.8 The Rabbit 303
 - 14.8.1 Excretion 304
 - 14.8.2 Husbandry 304
 - 14.8.3 Dosing Techniques 305
 - 14.8.4 Collection Techniques 307
 - 14.8.5 Study Designs 308
 - 14.8.6 Metabolism 308
- 14.9 Nonhuman Primates 315
 - 14.9.1 Environmental and Dietary Requirements 316
 - 14.9.2 Common Study Protocols 316
 - 14.9.3 General Study Activities 317
 - 14.9.4 Advantages and Disadvantages 319
- 14.10 Issues In Animal Model Selection 319
- 14.11 Statistics In Large Animal Studies 319
 - 14.11.1 Reasons for Small Sample Sizes in Large Animal Toxicology 319
 - 14.11.2 Cross-Sectional or Longitudinal Analysis? 320
 - 14.11.3 Repeated Measures: Advantages 320
 - 14.11.4 Repeated Measures: Disadvantages 320
 - 14.11.5 Common Practices in Large Animal Toxicology 320
 - 14.11.6 Univariate (Repeated Measures) Techniques: Advantages 320
 - 14.11.7 Univariate (Repeated Measures) Techniques: Disadvantages 321
 - 14.11.8 Multivariate Techniques: Advantages 321
 - 14.11.9 Multivariate Techniques: Disadvantages 321
 - 14.11.10 Some Other Design Factors to Be Considered in Analysis 321
 - 14.11.11 Covariates: Advantages 321
 - 14.11.12 Covariates: Disadvantages 321
 - 14.11.13 Missing Values 324
- 14.12 Read Across For Cross Species Data Integration 325
- 14.13 Summary 325
- References 325

15 Developmental And Reproductive Toxicity Testing 331

- 15.1 Introduction 331
- 15.2 Ich Study Designs 333
 - 15.2.1 Male and Female Fertility and Early Embryonic Development to Implantation 333

| | | |
|--------|----------------------------------------------------------------------------------------|-----|
| 15.2.2 | Embryo–Fetal Development | 335 |
| 15.2.3 | Adverse Effects | 335 |
| 15.2.4 | Pre- and Postnatal Development | 335 |
| 15.2.5 | Single-Study and Two-Study Designs for Rodents | 336 |
| 15.2.6 | Preliminary Studies | 336 |
| 15.2.7 | Potential Male Mediated Developmental Effects | 337 |
| 15.2.8 | Toxicokinetics | 338 |
| 15.2.9 | Timing of Studies | 338 |
| 15.3 | Methodological Issues | 339 |
| 15.3.1 | Control of Bias | 339 |
| 15.3.2 | Diet | 339 |
| 15.3.3 | Clinical Pathology | 340 |
| 15.3.4 | Gravid Uterine Weights | 340 |
| 15.3.5 | Implant Counts and Determination of Pregnancy | 341 |
| 15.3.6 | Fetal Examinations | 342 |
| 15.3.7 | Developmental Signs | 343 |
| 15.3.8 | Behavioral Tests | 344 |
| 15.3.9 | Detecting Effects on Male Reproduction | 344 |
| 15.4 | Developmental Studies In Primates | 344 |
| 15.5 | Data Interpretation | 345 |
| 15.5.1 | Use of Statistical Analyses | 345 |
| 15.5.2 | Potential Hazard Categories of Developmental Toxins | 347 |
| 15.5.3 | Associations Between Developmental and Maternal Toxicity | 349 |
| 15.5.4 | Assessment of Human Risk | 349 |
| 15.6 | Juvenile And Pediatric Toxicology | 351 |
| 15.7 | <i>In Vitro</i> Tests For Developmental Toxicity | 353 |
| 15.8 | Appraisal of Current Approaches For Determining Developmental And Reproductive Hazards | 357 |
| | References | 358 |

16 Carcinogenicity Studies

363

| | | |
|---------|---------------------------------------|-----|
| 16.1 | Introduction | 363 |
| 16.1.1 | History Of Xenobiotic Carcinogenesis | 365 |
| 16.2 | Mechanisms And Classes Of Carcinogens | 365 |
| 16.3 | Genotoxic Carcinogens | 365 |
| 16.4 | Epigenetic Carcinogens | 368 |
| 16.5 | Regulatory Requirements And Timing | 371 |
| 16.5.1 | Waivers of Required Testing | 371 |
| 16.6 | Species And Strain | 372 |
| 16.7 | Animal Husbandry | 373 |
| 16.8 | Dose Selection | 373 |
| 16.8.1 | Number of Dose Levels | 373 |
| 16.8.2 | Number of Control Groups | 374 |
| 16.8.3 | Criteria for Dose Selection | 374 |
| 16.9 | Group Size | 375 |
| 16.10 | Route Of Administration | 375 |
| 16.11 | Study Duration | 375 |
| 16.12 | Survival | 375 |
| 16.13 | End Points Measured | 376 |
| 16.14 | Transgenic Mouse Models | 378 |
| 16.14.1 | The Tg.AC Mouse Model | 378 |
| 16.14.2 | The Tg.rasH2 Mouse Model | 379 |
| 16.14.3 | The P53 ^{+/-} Mouse Model | 379 |
| 16.14.4 | The XPA ^{-/-} Mouse Model | 380 |

| | | |
|-----------|----------------------------------------------------------------------------------------------|------------|
| 16.15 | Interpretation Of Results: Criteria For A Positive Result | 381 |
| 16.16 | Statistical Analysis | 381 |
| 16.16.1 | Exact Tests | 383 |
| 16.16.2 | Trend Tests | 383 |
| 16.16.3 | Life Table and Survival Analysis | 384 |
| 16.16.4 | Peto Analysis | 384 |
| 16.16.5 | Methods to Be Avoided | 385 |
| 16.16.6 | Use of Historical Controls | 385 |
| 16.16.7 | Relevance to Humans | 385 |
| 16.17 | Weight-Of-Evidence Factors For Consideration In A Carcinogenicity Assessment Document (Cad) | 387 |
| 16.18 | Conclusions | 388 |
| | References | 389 |
| 17 | Histopathology and Clinical Pathology In Nonclinical Pharmaceutical Safety Assessment | 395 |
| 17.1 | Introduction | 395 |
| 17.1.1 | Pathological Techniques | 398 |
| 17.1.2 | Organ Weights | 398 |
| 17.2 | Clinical Pathology | 399 |
| 17.2.1 | Clinical Chemistry | 399 |
| 17.2.2 | Target Organ Toxicity Biomarkers | 399 |
| 17.2.3 | Integrated Analysis of Available Data | 400 |
| 17.2.4 | Oy Examination of Brain for CNS active Drugs | 400 |
| | References | 400 |
| 18 | Irritation And Local Tissue Tolerance In Pharmaceutical Safety Assessment | 403 |
| 18.1 | Introduction | 403 |
| 18.2 | Factors Affecting Irritation Responses And Test Outcome | 404 |
| 18.3 | Primary Dermal Irritation (PDI) Test | 404 |
| 18.4 | Other Nonparenteral Route Irritation Tests | 406 |
| 18.5 | Ocular Irritation Testing | 406 |
| 18.6 | Vaginal Irritation | 408 |
| 18.7 | Acute Primary Vaginal Irritation Study In The Female Rabbit | 409 |
| 18.7.1 | Repeated-Dose Vaginal Irritation in the Female Rabbit | 410 |
| 18.7.2 | Repeated-Dose Vaginal Irritation in the Ovariectomized Rats | 411 |
| 18.8 | Parenteral Irritation/Tolerance | 411 |
| 18.8.1 | Parenteral Routes | 411 |
| 18.8.2 | Test Systems for Parenteral Irritation | 412 |
| 18.9 | Problems In Testing (And Their Resolutions) | 414 |
| 18.9.1 | Alternatives to <i>In Vivo</i> Parenteral Tests | 415 |
| 18.10 | Phototoxicity | 415 |
| 18.10.1 | Theory and Mechanisms | 415 |
| 18.10.2 | Factors Influencing Phototoxicity/Photosensitization | 416 |
| 18.10.3 | Predictive Tests for Phototoxicity | 417 |
| 18.10.4 | 3T3 <i>In Vitro</i> Test | 418 |
| 18.10.5 | Rabbit Phototoxicity Test | 418 |
| 18.10.6 | Guinea Pig | 419 |
| 18.10.7 | Pyrogenicity | 420 |
| 18.11 | Hemocompatibility | 422 |
| 18.12 | Emetic Responses | 422 |
| | References | 422 |

| | |
|--------------------------------------------------------------------------------------|------------|
| 19 Pharmacokinetics And Toxicokinetics In Drug Safety Evaluation | 425 |
| 19.1 Introduction | 425 |
| 19.2 Regulations | 426 |
| 19.3 Principles | 426 |
| 19.3.1 Preliminary Work | 426 |
| 19.3.2 Absorption | 426 |
| 19.3.3 Distribution | 432 |
| 19.3.4 Metabolism/Biotransformation | 433 |
| 19.3.5 Excretion | 438 |
| 19.4 Pharmacokinetics | 439 |
| 19.5 Laboratory Methods | 439 |
| 19.5.1 Analytical Methods | 439 |
| 19.6 Sampling Methods And Intervals | 441 |
| 19.6.1 Blood | 441 |
| 19.6.2 Excreta | 442 |
| 19.6.3 Bile | 442 |
| 19.6.4 Expired Air | 442 |
| 19.6.5 Milk | 443 |
| 19.7 Study Types | 444 |
| 19.7.1 Whole-Body Autoradiography | 445 |
| 19.7.2 Mass Balance Studies | 446 |
| 19.8 Analysis of Data | 447 |
| 19.8.1 Use of Data from Metabolism and Pharmacokinetic Studies | 448 |
| 19.9 Noncompartmental Analysis | 448 |
| 19.10 Physiologically Based Pharmacokinetic (PBPK) Modeling | 448 |
| 19.11 Biologically Derived Materials | 449 |
| 19.11.1 Immunoassay Methods | 450 |
| 19.12 Points To Consider | 452 |
| References | 454 |
| | |
| 20 Safety Pharmacology | 457 |
| 20.1 Regulatory Requirements | 458 |
| 20.2 Study Designs And Principles | 459 |
| 20.3 Organ System-Specific Tests | 460 |
| 20.3.1 General Considerations in Selection and Design of Safety Pharmacology Studies | 460 |
| 20.3.2 Studies on Metabolites, Isomers, and Finished Products | 460 |
| 20.4 Cardiovascular | 460 |
| 20.4.1 Hemodynamics, ECG, and Respiration in Anesthetized Dogs or Primates | 461 |
| 20.4.2 Cardiac Conduction Studies | 461 |
| 20.4.3 Conscious Dog, Primate, or Minipig Telemetry Studies | 461 |
| 20.4.4 Six-Lead ECG Measurement in the Conscious Dog and Minipig | 461 |
| 20.4.5 Systems for Recording Cardiac Action Potentials | 462 |
| 20.4.6 Special Case (and Concern): QT Prolongation | 462 |
| 20.4.7 Some Specific Techniques Which Can Be Employed | 463 |
| 20.4.8 Relevance of hERG to QT Prolongation | 463 |
| 20.5 Central Nervous System | 463 |
| 20.5.1 Isolated Tissue Assays | 464 |
| 20.5.2 Electrophysiology Methods | 465 |
| 20.5.3 CNS Function: Electroencephalography | 465 |
| 20.5.4 Neurochemical and Biochemical Assays | 466 |

- 20.6 Respiratory/Pulmonary System 466
 - 20.6.1 Design of Respiratory Function Safety Studies 469
 - 20.6.2 Capnography 470
- 20.7 Secondary Organ System 471
 - 20.7.1 Gastric Emptying Rate and Gastric pH Changes: A New Model 471
- 20.8 Renal Function Tests 472
- 20.9 Summary 472
- References 472

21 Special Concerns For The Preclinical Evaluation Of Biotechnology Products **477**

- 21.1 Regulation 480
- 21.2 Preclinical Safety Assessment 481
- 21.3 Recombinant DNA Technology 484
 - 21.3.1 General Safety Issues 484
 - 21.3.2 Specific Toxicological Concerns 485
- 21.4 Immunogenicity/Allergenicity 485
- 21.5 Monoclonal Antibody Technology 485
 - 21.5.1 Toxicological Concerns with Monoclonal Antibodies 486
- 21.6 Bioprocess Technology 490
- 21.7 Gene Therapy Products 490
 - 21.7.1 Vectors 491
 - 21.7.2 Studies to Support the First Dose in Man 491
 - 21.7.3 Distribution of the Gene and Gene Product 492
 - 21.7.4 Studies to Support Multiple Doses in Humans 492
 - 21.7.5 Unnecessary Studies 492
 - 21.7.6 *Ex Vivo* Procedures 492
 - 21.7.7 Change of Gene or Vector 492
 - 21.7.8 Change of Route 493
 - 21.7.9 Insertional Mutagenesis 493
- 21.8 Vaccines 493
 - 21.8.1 Approaches to Vaccination 493
 - 21.8.2 Genetic Engineering and Vaccine Development 495
- 21.9 Special Challenges 497
 - 21.9.1 Purity and Homology 497
 - 21.9.2 Immunogenicity 498
- 21.10 Planning A Safety Evaluation Program 498
 - 21.10.1 The Producing System 498
 - 21.10.2 The Process 499
 - 21.10.3 The Product 499
 - 21.10.4 Biology of Bioengineered Products 499
 - 21.10.5 Animal Models 500
 - 21.10.6 Study Design 501
 - 21.10.7 Frequency and Route of Administration 502
 - 21.10.8 Duration 502
 - 21.10.9 Special Toxicity Testing 502
 - 21.10.10 Program Design Considerations 503
- 21.11 Challenges: Biosimilars 503
- References 504

22 Safety Assessment of Inhalant Drugs And Dermal Route Drugs **507**

- 22.1 Inhaled Therapeutics 507
- 22.2 The Pulmonary System 507
- 22.3 Penetration And Absorption of Inhaled Gases And Vapors 508

- 22.4 Deposition of Inhaled Aerosols 509
- 22.5 Absorption And Clearance of Inhaled Aerosols 510
- 22.6 Pharmacokinetics And Pharmacodynamics of Inhaled Aerosols 510
- 22.7 Methods For Safety Assessment of Inhaled Therapeutics 511
- 22.8 Parameters of Toxicity Evaluation 513
 - 22.8.1 The Inhaled “Dose” 513
 - 22.8.2 The Dose–Response Relationship 514
 - 22.8.3 Exposure Concentration Versus Response 515
 - 22.8.4 Product of Concentration and Duration (*Ct*) Versus Responses 515
 - 22.8.5 Units for Exposure Concentration 516
- 22.9 Inhalation Exposure Techniques 516
- 22.10 The Utility Of Toxicity Data 519
- 22.11 Formulation And Potential Mucosal Damage 519
 - 22.11.1 Methods To Assess Irritancy and Damage 520
- 22.12 Therapeutic Drug Delivery By The Dermal Route 520
- References 522

23 Special Case Products: Imaging Agents 529

- 23.1 Introduction 529
- 23.2 Imaging Agents 529
 - 23.2.1 Contrast Agents 530
 - 23.2.2 Diagnostic Radiopharmaceuticals 530
 - 23.2.3 Medical Imaging Agent Characteristics Relevant to Safety 531
 - 23.2.4 Performance of Nonclinical Safety Assessments 531
- References 533

24 Special Case Products: Drugs For Treatment Of Cancer 535

- 24.1 Introduction 535
 - 24.1.1 Animal Models 539
 - 24.1.2 Statistical Analysis of Study Results 540
- 24.2 How Oncology Is Different 540
- 24.3 Dose Conversions: Perspective 540
 - 24.3.1 The Use of the mg m^{-2} Dose Unit 540
 - 24.3.2 Calculations of Drug Dosages for Treatment 540
 - 24.3.3 Conversion of mg kg^{-1} BW Doses to Units of mg m^{-2} 541
- 24.4 Dose Setting In Oncology And Noninfectious Imminently Fatal Diseases: STD_{10} and HNSTD 541
 - 24.4.1 Determination of First in Human Dose Levels Based on Pivotal Toxicology Study Data 541
- References 541

25 Pediatric Product Safety Assessment (2006 Guidance, Including Juvenile And Pediatric Toxicology) 543

- 25.1 Introduction 543
 - 25.1.1 Scope of Nonclinical Safety Evaluation 545
 - 25.1.2 Timing of Juvenile Animal Studies in Relation to Clinical Testing 545
- 25.2 Issues To Consider Regarding Juvenile Animal Studies 546
 - 25.2.1 Developmental Stage of Intended Population 546
 - 25.2.2 Evaluating Data to Determine When Juvenile Animal Studies Should Be Used 546
 - 25.2.3 Considering Developmental Windows When Determining Duration of Clinical Use 546
 - 25.2.4 Timing of Exposure 547
 - 25.2.5 Selection of Study Models 547

- 25.3 General Considerations In Designing Toxicity Studies In Juvenile Animals 547
- 25.4 Study Designs And Considerations 547
- References 549

26 Use Of Imaging, Imaging Agents, And Radiopharmaceuticals In Nonclinical Toxicology 551

- 26.1 Introduction 551
 - 26.1.1 Multimodality Imaging Techniques 552
 - 26.1.2 Dynamic Molecular Imaging Techniques 552
- 26.2 X-RAY 552
 - 26.2.1 Angiography 553
- 26.3 Positron Emission Tomography (PET) 553
- 26.4 Single-Photon Emission Computed Tomography (SPECT) 553
- 26.5 Computed Tomography (CT) 554
- 26.6 Magnetic Resonance Imaging (MRI) 554
- 26.7 Optical Imaging 555
- 26.8 Ultrasound 556
 - 26.8.1 Echocardiography 556
- 26.9 Nanoparticle Contrast Agents 557
- 26.10 Radiopharmaceuticals 557
- 26.11 Applications Of Preclinical Imaging In Laboratory Animals 557
 - 26.11.1 Molecular Imaging as an ADME Platform in Drug Screen 557
 - 26.11.2 Preclinical Imaging in Oncology 558
 - 26.11.3 Preclinical Imaging of CNS Disease 562
 - 26.11.4 Preclinical Imaging of Autoimmune Disease 562
 - 26.11.5 Imaging Animal Model of Infectious Disease 562
 - 26.11.6 Preclinical Imaging of Cardiac Disease 563
- 26.12 Nonclinical Safety Assessment For Imaging Agents 563
- 26.13 Radiopharmaceuticals 565
- 26.14 Nonclinical Late Radiation Toxicity Studies 566
 - 26.14.1 Study Goals 566
- 26.15 Study Design 567
 - 26.15.1 Good Laboratory Practices 567
 - 26.15.2 Species Selection 567
 - 26.15.3 Timing of Study 567
 - 26.15.4 General Study Design 567
 - 26.15.5 Dose Levels 568
 - 26.15.6 Clinical Pathology 568
 - 26.15.7 Necropsy and Histopathology 568
- References 568

27 Occupational Toxicology In The Pharmaceutical Industry 571

- 27.1 Introduction 571
- 27.2 Occupational Toxicology Versus Drug Safety Evaluation 571
- 27.3 Regulatory Pressures In The United States And The European Community 573
- 27.4 Organizational Structure 574
- 27.5 Activities 575
 - 27.5.1 Data Evaluation and Dissemination 575
 - 27.5.2 Data Development 576
 - 27.5.3 Occupational Exposure Limits (OELs) 579
 - 27.5.4 Hazard Assessment 579
 - 27.5.5 Employee Training 580
- 27.6 Conclusion 582
- References 582

| | |
|-------------------------------------------------------------------------------------------------------------------------------|------------|
| 28 Strategy and Phasing For Nonclinical Drug Safety Evaluation In The Discovery and Development of Pharmaceuticals | 585 |
| 28.1 Introduction | 585 |
| 28.2 Regulatory Requirements | 587 |
| 28.3 Essential Elements of Project Management | 590 |
| 28.4 Screens: Their Use And Interpretation In Safety Assessment | 592 |
| 28.4.1 Characteristics of Screens | 594 |
| 28.5 Strategy And Phasing | 596 |
| 28.6 Critical Considerations | 600 |
| 28.7 Special Cases in Safety Assessment | 600 |
| 28.8 Potential Market Withdrawal Issues | 601 |
| 28.9 Summary | 601 |
| References | 602 |
| | |
| 29 The Application of <i>In Vitro</i> Techniques In Drug Safety Assessment | 603 |
| 29.1 Introduction | 603 |
| 29.2 <i>In Vitro</i> Testing In Pharmaceutical Safety Assessment | 605 |
| 29.3 Defining Testing Objective | 608 |
| 29.3.1 Objectives Behind Data Generation And Utilization | 608 |
| 29.4 Test Systems: Characteristics, Development, And Selection | 608 |
| 29.5 <i>In Vitro</i> Models | 609 |
| 29.6 Lethality | 610 |
| 29.6.1 Ocular Irritation | 613 |
| 29.6.2 Dermal Irritation | 614 |
| 29.6.3 Irritation of Parenterally Administered Pharmaceuticals | 616 |
| 29.6.4 Sensitization and Photosensitization | 617 |
| 29.6.5 Phototoxicity and Photosensitization | 617 |
| 29.6.6 Pyrogenicity | 618 |
| 29.6.7 Developmental Toxicity | 618 |
| 29.6.8 Target Organ Toxicity Models | 619 |
| 29.7 <i>In Silico</i> Methods | 623 |
| 29.8 The Final Frontier And Barrier: Regulatory Acceptance | 623 |
| 29.9 Summary | 625 |
| References | 625 |
| Further Reading | 631 |
| | |
| 30 Evaluation Of Human Tolerance And Safety In Clinical Trials: Phase I And Beyond | 635 |
| 30.1 The Pharmaceutical Clinical Development Process And Safety | 635 |
| 30.1.1 Pharmacokinetics | 641 |
| 30.1.2 Safety of Clinical Trial Subjects | 643 |
| 30.2 Limitations On/Of Clinical Trials | 649 |
| 30.3 The Clinical Trial Process | 650 |
| 30.3.1 Development of An Application Unrelated To Original Approved Use | 652 |
| 30.4 Institutional Review Boards (Irb)/Ethics Committees In The Clinical Trial Process | 654 |
| 30.4.1 Legal Authority and Responsibilities for IRBs | 654 |
| 30.4.2 Duties of IRBs | 655 |
| 30.4.3 Informed Consent | 655 |
| 30.5 Drug Formulations And Excipients | 656 |
| 30.5.1 Route of Administration | 656 |

- 30.6 Phase I Designs 657
 - 30.6.1 First Administration: Single Dose Escalating (SDE) 658
 - 30.6.2 First Administration in Humans: Multiple Dose Escalating (MDE) 660
- 30.7 Clinical Trial Safety Indicators 660
 - 30.7.1 Overall Approach to Assessing Safety 661
 - 30.7.2 Precautions 662
 - 30.7.3 Clinical Chemistry 664
 - 30.7.4 Urinalysis 665
 - 30.7.5 Urine Screens 666
 - 30.7.6 Identifying New Diagnostic Laboratory Tests 666
 - 30.7.7 Ophthalmological Examination 666
 - 30.7.8 Dermatological Examinations 666
 - 30.7.9 Cardiovascular Safety 666
 - 30.7.10 Deaths in Clinical Trials 667
 - 30.7.11 Behavioral Rating Scales, Performance, Personality, and Disability Tests 668
 - 30.7.12 Adult Behavioral Rating Scales 668
 - 30.7.13 Pediatric Behavioral Rating and Diagnostic Scales 670
 - 30.7.14 Psychometric and Performance Tests 671
 - 30.7.15 Personality Tests 673
- 30.8 Assessment Of Unwanted Drug Effects 673
 - 30.8.1 Separation of Adverse Reactions from Placebo Reactions 673
- 30.9 Recent Changes In Safety Related Requirements For Initial Clinical Requirements 678
- References 678

31 Postmarketing Safety Evaluation: Monitoring, Assessing, And Reporting of Adverse Drug Responses (ADRs) 683

- 31.1 Causes of Safety Withdrawals 691
- 31.2 Regulatory Requirements 691
 - 31.2.1 The 15-Day Report Versus The US Periodic Report 692
- 31.3 Management Of Adr And Ade Data 694
 - 31.3.1 Sources of Data 694
 - 31.3.2 Clinical Trials 694
 - 31.3.3 Post-marketing Surveillance Studies 694
 - 31.3.4 Spontaneous Reports 694
 - 31.3.5 Literature 695
 - 31.3.6 Searching for ADRs in the Literature 695
 - 31.3.7 Information Required for Reports 695
 - 31.3.8 Adverse Drug Reaction Forms and Form Design 696
 - 31.3.9 Computerization of Drug Safety Data: Data Collection and Input 696
 - 31.3.10 Medical and Drug Terminology 696
 - 31.3.11 Dictionaries 698
 - 31.3.12 Medical Term Coding Dictionaries 698
 - 31.3.13 Medical Dictionary for Regulatory Activities 698
 - 31.3.14 Periodic Reports 699
- 31.4 Causality Assessment 700
 - 31.4.1 Aims of Causality Assessment 700
- 31.5 Courses Of Corrective Action 700
- 31.6 Legal Consequences Of Safety Withdrawal 701
 - 31.6.1 FDA Tools for Risk Management 701
 - 31.6.2 Tier 1: Mandatory Studies 702
 - 31.6.3 Tier 2: Labeling and Assessment 703

- 31.6.4 Tier 3: Enhanced Communication 703
- 31.6.5 Tier 4: Safe Use Restriction Defined by Provider 703
- 31.6.6 Tier 5: Safe Use Restriction Defined by Patient 704

References 704

32 Statistics In Pharmaceutical Safety Assessment 707

- 32.1 Introduction 707
 - 32.1.1 Bias and Chance 709
 - 32.1.2 Hypothesis Testing and Probability (p) Values 709
 - 32.1.3 Multiple Comparisons 710
 - 32.1.4 Estimating the Size of the Effect 710
 - 32.1.5 Functions of Statistics 711
 - 32.1.6 Descriptive Statistics 712
- 32.2 Experimental Design 713
 - 32.2.1 Choice of Species and Strain 713
 - 32.2.2 Sampling 713
 - 32.2.3 Dose Levels 714
 - 32.2.4 Number of Animals 714
 - 32.2.5 Duration of the Study 714
 - 32.2.6 Stratification 715
 - 32.2.7 Randomization 715
 - 32.2.8 Adequacy of Control Group 715
- 32.3 Data Recording 718
- 32.4 Generalized Methodology Selection 719
- 32.5 Statistical Analysis: General Considerations 719
 - 32.5.1 Variables to Be Analyzed 719
 - 32.5.2 Combination of Observations (Such as Pathological Conditions) 721
 - 32.5.3 Taking Severity into Account 722
 - 32.5.4 Using Simple Methods Which Avoid Complex Assumptions 722
 - 32.5.5 Using All the Data 722
 - 32.5.6 Combining, Pooling, and Stratification 722
 - 32.5.7 Trend Analysis, Low-Dose Extrapolation, and NOEL Estimation 723
 - 32.5.8 Need for Age Adjustment 725
 - 32.5.9 Need to Take Context of Observation into Account 726
 - 32.5.10 Experimental and Observational Units 726
 - 32.5.11 Missing Data 726
 - 32.5.12 Use of Historical Control Data 727
 - 32.5.13 Methods for Data Examination and Preparation 727
 - 32.5.14 Scattergram 727
 - 32.5.15 Bartlett's Test for Homogeneity of Variance 729
 - 32.5.16 Statistical Goodness-of-Fit Tests 730
 - 32.5.17 Randomization 731
 - 32.5.18 Transformations 731
 - 32.5.19 Exploratory Data Analysis 732
- 32.6 Hypothesis Testing Of Categorical And Ranked Data 733
 - 32.6.1 Fisher's Exact Test 733
 - 32.6.2 2×2 Chi-Square 734
 - 32.6.3 $R \times C$ Chi-Square 734
 - 32.6.4 Wilcoxon Rank-Sum Test 735
 - 32.6.5 Distribution-Free Multiple Comparison 736
 - 32.6.6 Mann-Whitney U Test 736
 - 32.6.7 Kruskal-Wallis Nonparametric ANOVA 737
 - 32.6.8 Log-Rank Test 737

| | | |
|-----------|--------------------------------------------------------------------------------------------------------------|------------|
| 32.7 | Hypothesis Testing: Univariate Parametric Tests | 738 |
| 32.7.1 | Student's <i>t</i> -Test (Unpaired <i>t</i> -Test) | 739 |
| 32.7.2 | Cochran <i>t</i> -Test | 739 |
| 32.7.3 | <i>F</i> -Test | 740 |
| 32.7.4 | Analysis of Variance (ANOVA) | 740 |
| 32.7.5 | Post Hoc Tests | 741 |
| 32.7.6 | Duncan's Multiple Range Test | 741 |
| 32.7.7 | Groups with Equal Number of Data ($N_1 = N_2$) | 741 |
| 32.7.8 | Groups with Unequal Number of Data ($N_1 \neq N_2$) | 742 |
| 32.7.9 | Scheffe's Multiple Comparisons | 742 |
| 32.7.10 | Dunnett's <i>t</i> -Test | 742 |
| 32.7.11 | Williams' <i>t</i> -Test | 743 |
| 32.7.12 | Analysis of Covariance | 743 |
| 32.7.13 | Modeling | 744 |
| 32.7.14 | Linear Regression | 745 |
| 32.7.15 | Probit/Log Transforms and Regression | 745 |
| 32.7.16 | Nonlinear Regression | 746 |
| 32.7.17 | Correlation Coefficient | 747 |
| 32.7.18 | Kendall's Coefficient of Rank Correlation | 748 |
| 32.7.19 | Trend Analysis | 748 |
| 32.8 | Methods For The Reduction Of Dimensionality | 748 |
| 32.8.1 | Classification | 749 |
| 32.8.2 | Statistical Graphics | 750 |
| 32.8.3 | Multidimensional and Nonmetric Scaling | 751 |
| 32.8.4 | Cluster Analysis | 753 |
| 32.8.5 | Fourier or Time Analysis | 753 |
| 32.8.6 | Life Tables | 754 |
| 32.9 | Meta-Analysis | 755 |
| 32.9.1 | Selection of the Studies to Be Analyzed | 755 |
| 32.9.2 | Pooled (Quantitative) Analysis | 755 |
| 32.9.3 | Methodological (Qualitative) Analysis | 756 |
| 32.10 | Bayesian Inference | 756 |
| 32.10.1 | Bayes' Theorem and Evaluation of Safety Assessment Studies | 756 |
| 32.10.2 | Bayes' Theorem and Individual Animal Evaluation | 757 |
| 32.11 | Data Analysis Applications In Safety Assessment Studies | 758 |
| 32.11.1 | Body and Organ Weights | 759 |
| 32.11.2 | Clinical Chemistry | 760 |
| 32.11.3 | Hematology | 760 |
| 32.11.4 | Histopathological Lesion Incidence | 760 |
| 32.11.5 | Carcinogenesis | 761 |
| | References | 762 |
| 33 | Combination Products: Drugs and Devices | 767 |
| 33.1 | Combination Products | 767 |
| 33.1.1 | Historical Background | 767 |
| 33.1.2 | Future Trends | 768 |
| | References | 775 |
| 34 | Qualification Of Impurities, Degradants, Residual Solvents, Metals, and Leachables in Pharmaceuticals | 777 |
| 34.1 | Impurities | 777 |
| 34.2 | Residual Solvents | 782 |

| | | |
|-----------|---------------------------------------------------------------------------------------------------------------|------------|
| 34.3 | Extractables And Leachables | 784 |
| 34.4 | Residual Metals And Elements | 785 |
| | References | 786 |
| 35 | Tissue, Cell, and Gene Therapy | 789 |
| 35.1 | Safety Assessment of Cell Therapy (Ct) Products | 790 |
| 35.1.1 | Recommendations for General Preclinical Program Design | 790 |
| 35.1.2 | Model Species Selection | 790 |
| 35.1.3 | Selection of Animal Models of Disease/Injury | 790 |
| 35.1.4 | Information Describing Limitations of Potential Animal Model(s) | 791 |
| 35.1.5 | Information Supporting the Choice of Animal Model(s) | 791 |
| 35.1.6 | Proof-of-Concept (POC) Studies | 791 |
| 35.1.7 | Toxicology Studies | 792 |
| 35.1.8 | Product Delivery Considerations | 793 |
| 35.1.9 | Study Designs | 794 |
| 35.1.10 | CT Products with Implantable Scaffolds | 796 |
| 35.2 | Nonclinical Safety Assessment of Gene Therapy Products (GTPS) | 796 |
| 35.2.1 | CBER | 796 |
| 35.2.2 | NIH | 796 |
| 35.2.3 | Study Designs | 797 |
| 35.2.4 | <i>Ex Vivo</i> Genetically Modified Cells | 798 |
| 35.2.5 | Biodistribution Considerations | 798 |
| 35.3 | Definitions | 799 |
| | References | 799 |
| 36 | Adverse Outcome Pathways in Drug Safety Assessment | 801 |
| 36.1 | Introduction | 801 |
| 36.2 | Initial Steps | 801 |
| 36.3 | Test Article – Confirming Identity And Stability | 801 |
| 36.4 | Formulation | 801 |
| 36.5 | Test Species – Animal Models | 802 |
| 36.6 | Dose Level Selection And Dosing Errors | 802 |
| 36.7 | Poor Planning | 802 |
| 36.8 | Pay Attention To The Regulatory Clock and Changes In Requirements and Guidelines | 802 |
| 36.9 | Most Advances In Safety Assessment are Small | 803 |
| | References | 803 |
| | Appendix A: Selected Regulatory and Toxicological Acronyms | 805 |
| | Appendix B: Definition Of Terms And Lexicon of “Clinical” Observations in Nonclinical (Animal) Studies | 807 |
| | Appendix C: Notable Regulatory Internet Addresses | 811 |
| | Appendix D: Glossary Of Terms Used in The Clinical Evaluation of Therapeutic Agents | 817 |
| | Appendix E: Common Vehicles For The Nonclinical Evaluation of Therapeutic Agents | 821 |
| | Appendix F: Global Directory of Contract Toxicology Labs | 919 |
| | INDEX | 945 |

PREFACE

This fourth edition of *Drug Safety Evaluation* is a revision of the third edition that maintains the central objective of presenting an all-inclusive practical guide for those who are responsible for ensuring the safety of drugs and biologics to patients and shepherding valuable candidates to market, healthcare providers, those involved in the manufacture of medicinal products, and all those who need to understand how the safety of these products is evaluated. The many changes in regulatory requirements, pharmaceutical development, technology, and the effects of Covid on our society and science have required both extensive revision to every chapter and the addition of four new chapters.

This practical guide presents a road map for safety assessment as an integral part of the development of new drugs and therapeutics. Individual chapters also address specific approaches to evaluation hazards, including problems that are encountered and their solutions. Also covered are the scientific and philosophical bases for evaluation of specific concerns (e.g. carcinogenicity and development toxicity) to provide both understanding and guidance for approaching the new problems that have come to face both our society and the new challenges they brought. *Drug Safety Evaluation* specifically aims at the pharmaceutical and biotechnology industries. It addresses not only the general cases for safety evaluation of small and large molecules but also all of the significant major subcases: imaging agents, dermal and inhalation route drugs, vaccines, and gene therapy products. It is hoped that the approaches and methodologies presented here will show a utilitarian yet scientifically valid path to the everyday challenges of safety evaluation and the problem solving that is required in drug discovery and development.

Shayne Cox Gad
Raleigh, North Carolina

ABOUT THE AUTHORS

Shayne Cox Gad, B.S. (Whittier College, Chemistry and Biology, 1971) and Ph.D. in Pharmacology/Toxicology (Texas, 1977) DABT, ATS, is the principal of Gad Consulting Services, a 24-year-old consulting firm with 7 employees and more than 450 clients (including 200 pharmaceutical companies in the United States and 50 overseas). Before this, he served in the director level and in the abovementioned positions at Searle, Synergen, and Becton Dickinson. He has published 48 books and more than 350 chapters, articles, and abstracts in the fields of toxicology, statistics, pharmacology, drug development, and safety assessment. He has more than 39 years of broad-based experience in toxicology, drug and device development, statistics, and risk assessment. He has specific expertise in neurotoxicology, *in vitro* methods, cardiovascular toxicology, inhalation toxicology, immunotoxicology, and genotoxicology. He was the past president of the American College of Toxicology (ACT), the Roundtable of Toxicology Consultants, and three of Society of Toxicology (SOT's) specialty sections. He has direct involvement in the preparation of Investigational New Drugs (INDs) (110 successfully to date), New Drug Application (NDA), Product License Application (PLA), Abbreviated New Drug Application (ANDA), 501(k), Investigational Device Exemption (IDE), Common Technical Document (CTD), clinical databases for phase 1 and 2 studies, and PMAs. He has consulted for Food and Drug Administration (FDA), Environmental Protection Agency (EPA), and National Institutes of Health (NIH) and has trained reviewers and been an expert witness for FDA. He has also conducted the triennial toxicology salary survey as a service to the profession for the past 27 years.

Dr. Shayne Cox Gad is also a retired line officer in Navy.

Dexter W. Sullivan Jr., MS, DABT, is the senior toxicologist of Gad Consulting Services where he consults on issues related to toxicology, pharmaceutical and medical device development, regulatory affairs, and human health risk assessment. He has authored and co-authored over 40 peer-reviewed publications, journal articles, book chapters, and abstracts in the abovementioned fields. Dexter is a Diplomate of the American Board of Toxicology and a member of the SOT as well as a member of the ACT. As an active member of the ACT, he has served as a member of the ACT Social Media Subcommittee and currently chairs the ACT Webinar Subcommittee. As a service to the scientific community, he has co-authored the toxicology salary survey for the past 10 years. As a consultant, Dexter has supported the successful preparation and filings for countless INDs as well as NDAs. He has consulted for EPA and performed thousands of human health risk assessments, including assessments for the EPA National Center for Environmental Assessment (NCEA) and the EPA Office of Water (OW). Dexter received his BS in Toxicology from the University of Louisiana at Monroe and his MS in Biology from Western Kentucky University.

1

THE DRUG DEVELOPMENT PROCESS AND THE GLOBAL PHARMACEUTICAL MARKETPLACE

1.1 INTRODUCTION

Pharmaceuticals are a global industry, grossing \$1.25 trillion (US dollars) in 2019. They are developed to benefit (and sell to) individuals and societies worldwide. Their effectiveness and costs affect, directly or indirectly, all of us.

This fourth edition focuses (as its predecessors did) on the assessment of the safety of new drugs. In the broadest sense, this means it must address not only the traditional “small molecules” that have dominated the field for the last century and the large therapeutic molecules derived from biotechnology sources but also vaccines, biologics such as blood and blood products, cell therapies, and excipients. The globalization of the regulation of the safety, efficacy, and manufacture of pharmaceutical products comes from the success of the International Conference on Harmonization (ICH) process. But, as will be seen, the same globalization of the industry and continuous advances of science have also led to market diversification of the types and uses of drugs, and with this, regulatory drug safety evaluation requirements continue to fragment, which has made things more complex rather than simpler (Alder and Zbinden, 1988; Gad, 2018; Norman 2016a, 2016b).

1.2 THE MARKETPLACE

The world marketplace for drugs is large, although the majority of sales are in three regions: in 2019 about 35% of the pharmaceutical market (by sales) resided in the United States, 24% in Europe, 12% in Japan, with the remaining 29% in emerging markets (Christel, 2019). This does not mean, however, that marketing applicants can or should ignore the requirements of other countries, for example, China and

Indonesia. Approval processes in these countries can at times be as rigorous as in any other regulatory authority’s domain.

Pharmaceuticals in all their forms compete today as part of a global market, though one which serves (and is available to) different parts of the world’s population to varying extents.

The term “pharmaceuticals” is here used in the broadest sense of man-made therapeutics: small molecules, large protein moieties, vaccines, blood products, and as must be, their attendant components (excipients, impurities, and all) to different degrees and in different types of products.

According to the Statista (2019) global pharmaceutical market and therapy report, the global market for regulated drugs (as differentiated from dietary supplements, herbal products, and nutraceuticals) is estimated to have been some \$1.25 trillion in 2019 (US dollars) (Drugs.com, 2014). In 2015, there were 143 individual products with annual sales in excess of \$1 billion (i.e., “blockbusters”) which have tended to be the focus of pharmaceutical development until recently and the impending demise of patents on which is changing the industry (Table 1.1). It remains to be seen how the Covid-19 pandemic influences 2020 and 2021 statistics.

This concentration of total sales in a limited number of products (e.g., there are currently more than 22 000 approved prescription drugs in the United States) is widely held to have distorted the therapeutic aspects of new drug development but is now starting to undergo change (back to) a paradigm that looks at a decreased emphasis on the billion dollar “blockbuster” drugs.

Widely misunderstood is the extent and diversity of the pharmaceutical R&D sector. While precise numbers are unavailable (and meaningless, as companies are continuously being started, merged, or going out of business, though the overall trend is to increased numbers), best estimates place the number of companies directly involved in discovering

TABLE 1.1 Top 20 Selling Pharmaceuticals (2019) (Sharma, 2020)

| Rank | Drug | Current manufacturer | Total sales 2019 | Total sales 2018 | Total sales 2017 | Primary disease/ medical use | Route(s) |
|------|-----------------------------|----------------------------------------------------------------|------------------|------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| | | | In billions, USD | | | | |
| 1 | Humira (adalimumab) | AbbVie, Inc. and Eisai | 19.16 | 20.3 | Not available | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, adult, and pediatric Crohn's disease, plaque psoriasis, juvenile idiopathic arthritis, ulcerative colitis, axial spondyloarthropathy (EU only), hidradenitis suppurativa, pediatric enthesitis-related arthritis (EU only), panuveitis, Behcet's disease (Japan only) | Injection |
| 2 | Keytruda (pembrolizumab) | Merck & Co. | 11.08 | 7.17 | 3.8 | Non-small cell lung cancer, melanoma, head, and neck squamous cell cancer, urothelial bladder cancer, kidney cancer, microsatellite instability- high cancer, classical Hodgkin lymphoma, gastric cancer, cervical cancer, primary mediastinal B-cell lymphoma, hepatocellular carcinoma, Merkel cell carcinoma | Injection |
| 3 | Revlimid (lenalidomide) | Bristol-Myers Squibb and Ono Pharmaceutical | 9.37 | 9.69 | 8.19 | Anemia, multiple myeloma, Oral myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma | Oral |
| 4 | Elquis (apixaban) | Bristol-Myers Squibb | 7.92 | 9.87 | 7.4 | Reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; deep vein thrombosis and pulmonary embolism | Oral |
| 5 | Eylea (aflibercept) | Regeneron Pharmaceutical, Bayer, Saten Pharmaceutical | 7.54 | 7.16 | 6.39 | Neovascular (wet) age- related macular degeneration, macular edema following central retinal vein occlusion, diabetic macular edema, diabetic retinopathy | Intraocular |

(Continued)

TABLE 1.1 (Continued)

| Rank | Drug | Current manufacturer | Total sales 2019 | Total sales 2018 | Total sales 2017 | Primary disease/ medical use | Route(s) |
|------|--------------------------------------------------------------|-------------------------------------------------------------|------------------|------------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | | | In billions, USD | | | | |
| 6 | Avastin (bevacizumab) | Roche, Chugai Pharmaceutical | 7.3 | 7 | 6.8 | Anti-angiogenic, brain tumor, certain types of cancers of the kidney, lung, colon, rectum, cervix, ovary, or fallopian tube. Cancer of the membrane lining the internal organs in the abdomen | IV |
| 7 | Opdivo (nivolumab) | Bristol-Myers Squibb, Ono Pharmaceutical | 7.2 | 7.55 | 5.76 | Melanoma, nonsmall cell lung cancer, small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma | IV |
| 8 | Rituxan/MabThera (Rituximab) | Roche, Chungai Pharmaceutical, Zenyaku Kogyo | 6.9 | 6.9 | 7.55 | Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, pemphigus vulgaris, B-cell lymphoproliferative disorders (Japan), pediatric nephrotic syndrome (Japan) | IV |
| 9 | Stelara (ustekinumab) | Johnson & Johnson | 6.36 | 5.16 | 4 | Plaque psoriasis, Crohn's disease, psoriatic arthritis | Injection |
| 10 | Herceptin (trastuzumab) | Roche, Chugai Pharmaceutical | 6.23 | 7.14 | 7.17 | Breast cancer | IV |
| 11 | Pevnar 13/Prevenar 13 (pneumococcal conjugate vaccine) | Pfizer, Daewoong Pharmaceutical | 5.84 | 5.8 | 5.69 | Vaccine, pneumococcal disease, and pneumococcal pneumonia | Injection |
| 12 | Enbrel (etanercept) | Amgen, Pfizer, Takeda Pharmaceutical | 5.22 | 7.13 | 8.23 | Arthritis, or ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and polyarticular juvenile idiopathic arthritis | Injection |
| 13 | Ibrance (Palbociclib) | Pfizer | 4.96 | 4.12 | 3.13 | Breast cancer | IV |
| 14 | Remicade (Infliximab) | Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma | 4.36 | 6.44 | 7.73 | Arthritis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, plaque psoriasis | IV |

(Continued)

TABLE 1.1 (Continued)

| Rank | Drug | Current manufacturer | Total sales 2019 | Total sales 2018 | Total sales 2017 | Primary disease/ medical use | Route(s) |
|------|--------------------------------------------------------------------------------------------------|---------------------------------------|------------------|------------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | | | In billions, USD | | | | |
| 15 | Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) | Gilead Sciences, Torii Pharmaceutical | 3.93 | 4.69 | 3.73 | HIV-1 infection | Oral |
| 16 | Imbruvica (ibrutinib) | Johnson & Johnson, AbbVie | 3.4 | 5.58 | 4.04 | Mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, chronic graft versus host disease | Oral |
| 17 | Lyrica (pregabalin) | Pfizer Inc. | 3.32 | 4.97 | 5.07 | Control of seizures, fibromyalgia, diabetic neuropathy, herpes zoster, post-herpetic neuralgia, or neuropathic pain associated with spinal cord injury. | Oral |
| 18 | Victoza (liraglutide injection) | Novo Nordisk | 3.29 | 3.85 | 3.67 | Glycemic control in type 2 diabetes mellitus patients, reduce adverse cardiovascular events in adults with T2 diabetes mellitus | Injection |
| 19 | Neulasta/Peglasta/G-Lasta (pegfilgrastim injection) | Amgen, Kyowa Hakko Kirin | 3.22 | 4.69 | 4.72 | Neutropenia caused by receiving chemotherapy, febrile neutropenia | Injection |
| 20 | Truvada | Gilead Sciences, Torii Pharmaceutical | 2.81 | 3.01 | 3.17 | HIV-1 | Oral |

Source: pharmashots.com (2020).

and developing new drugs in the United States and Canada at about 3800, 10% of which are publicly traded. There are an equal number in Europe and significant numbers in many other parts of the world (Japan, China, Australia, India, and Israel, to name just a few other countries). While most of the public focuses on very large companies, such as those in Table 1.2, there are many more midsize and small companies.

Starting in 1984 with the Drug Price Competition and Patent Term Restoration Act (better known as the Hatch–Waxman Act), members of small-molecule drugs leaving the

period of patent protection could be introduced into the marketplace by an ANDA-approved route—a much simpler and quicker route to market approval. Such generics constituted 81% of the prescriptions in the United States by 2019, though their market share by sales (\$260 billion in 2012) is only 21% of revenues (Statista, 2019).

One factor to consider in the regulatory requirements for early development of new therapeutic entities is the higher degree to which costs may present barriers to smaller, innovative companies. This is commonly overlooked by many